For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
After finishing at $2.29 in the prior trading day, ProKidney Corp (NASDAQ: PROK) closed at $2.28, down -0.44%. In other words, the price has decreased by -$0.44 from its previous closing price. On the day, 0.51 million shares were traded. PROK stock price reached its highest trading level at $2.35 during the session, while it also had its lowest trading level at $2.2501.
Ratios:
Our goal is to gain a better understanding of PROK by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.32 and its Current Ratio is at 10.32.
Upgrades & Downgrades
In the most recent recommendation for this company, H.C. Wainwright on December 16, 2025, initiated with a Buy rating and assigned the stock a target price of $12.
On June 30, 2025, BofA Securities Downgraded its rating to Underperform which previously was Neutral but kept the price unchanged to $1.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 13 ’25 when Pereira Brian JG sold 502,136 shares for $2.37 per share. The transaction valued at 1,190,062 led to the insider holds 0 shares of the business.
Pereira Brian JG sold 255,026 shares of PROK for $694,515 on Nov 12 ’25. The Director now owns 54,333 shares after completing the transaction at $2.72 per share. On Nov 12 ’25, another insider, Brian Pereira, who serves as the Director of the company, bought 675,234 shares for $2.70 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PROK now has a Market Capitalization of 685902336 and an Enterprise Value of 1381592576. For the stock, the TTM Price-to-Sale (P/S) ratio is 926.89. Its current Enterprise Value per Revenue stands at 1856.979 whereas that against EBITDA is -8.395.
Stock Price History:
The Beta on a monthly basis for PROK is 1.82, which has changed by 0.38787878 over the last 52 weeks, in comparison to a change of 0.17287207 over the same period for the S&P500. Over the past 52 weeks, PROK has reached a high of $7.13, while it has fallen to a 52-week low of $0.46. The 50-Day Moving Average of the stock is -3.78%, while the 200-Day Moving Average is calculated to be 11.64%.
Shares Statistics:
The stock has traded on average 1.37M shares per day over the past 3-months and 1083500 shares per day over the last 10 days, according to various share statistics. A total of 135.98M shares are outstanding, with a floating share count of 103.33M. Insiders hold about 25.45% of the company’s shares, while institutions hold 28.50% stake in the company. Shares short for PROK as of 1767139200 were 15182669 with a Short Ratio of 11.08, compared to 1764288000 on 14786117. Therefore, it implies a Short% of Shares Outstanding of 15182669 and a Short% of Float of 14.760000000000002.
Earnings Estimates
. The current market rating for ProKidney Corp (PROK) reflects the collective analysis of 6.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.16, with high estimates of -$0.16 and low estimates of -$0.16.
Analysts are recommending an EPS of between -$0.41 and -$1.07 for the fiscal current year, implying an average EPS of -$0.59. EPS for the following year is -$0.64, with 6.0 analysts recommending between -$0.42 and -$1.2.
Revenue Estimates
5 analysts predict -$39.4k in revenue. The current quarter. It ranges from a high estimate of $250k to a low estimate of -$447k. As of. The current estimate, ProKidney Corp’s year-ago sales were $76k
